Prioritizing R&D funding and considering dividends from future profits
First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2020.
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
32 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「The company has made every effort to improve its performance, making the achievement of stable profitability over the long term its highest priority. However, in light of its performance for the current fiscal year, it wishes not to pay a dividend for the current fiscal year. It intends to consider paying dividends in the future, taking its operating results and financial position into account.」
The company continues not to pay dividends due to indication expansion, new product development, investment in personnel and equipment, and preparations for pandemics and other events, prioritising stable profitability. - FY2019RestatedAnnual report
「Making the achievement of stable profitability over the long term its highest priority, the company wishes not to pay a dividend for the current fiscal year. It intends to consider paying dividends in the future, taking its operating results and financial position into account.」
The company has indicated that it will continue not to pay dividends due to multiple clinical trials, indication expansion, securing personnel and capital investment, prioritising the achievement of stable profitability. - FY2016First statedAnnual report
「The company is in the stage of making upfront investments in its regenerative medicine products business and needs to continue its research and development activities. It therefore prioritises securing research and development funding. At the same time, it recognises the return of profits to shareholders as an important management issue and intends to consider paying dividends in the future, taking its operating results and financial position into account.」
The company has indicated that it will not pay dividends at present, prioritising the securing of research and development funding while considering future dividends.